Satisfaction with care in men with prostate cancer

Abstract

Purpose This study aims to describe: (a) the proportion of prostate cancer patients satisfied with treatment, (b) how satisfaction changes after treatment, and (c) predictors of patient satisfaction including demographic, symptom‐related and treatment variables. Method Self‐reported quality of life and satisfaction questionnaire (UCLA Expanded Prostate Cancer Index Composite [EPIC] 26), and demographics were obtained from the South Australian Prostate Cancer Clinical Outcomes Collaborative (SA‐PCCOC) database. Responses were obtained pre‐treatment (radical prostatectomy or external beam radiation therapy) and 6, 12 and 24 months post‐treatment, for patients diagnosed between 2009 and 2013. Mixed‐effects models were used to estimate mean and change in satisfaction, and to identify predictive factors. Results SA‐PCCOC is a prospective, prostate cancer specific registry established in 1998, of which 1,713 patients were eligible for inclusion and 434 available for analysis. Overall, the majority of patients who completed questionnaires were satisfied with their treatment (82%). Satisfaction with care did not change over time post‐treatment in multivariable analysis (p = 0.08). Conclusions Satisfaction with treatment is typically high among prostate cancer patients. Satisfaction did not change with time after treatment and appears to be associated with baseline hormonal scores and changes in hormonal scores post‐treatment.

Shared decision‐making in routine breast cancer care in Germany—A cross‐sectional study

“…Furthermore, there is little available information how satisfied cancer patients are with quality of care. 14 The majority of 434 patients suffering from prostate cancer were satisfied with their treatment in a current study 15 and the satisfaction rates among 191 patients with advanced cancer were high, too. 16 Satisfaction with the medical decisions made, evaluated across the entire breast cancer therapy, was high in all patients (26.0 in mean), and it was numerically higher in patients after mastectomy than in patients after BCS.…”

“…Furthermore, there is little available information how satisfied cancer patients are with quality of care 14 . The majority of 434 patients suffering from prostate cancer were satisfied with their treatment in a current study 15 and the satisfaction rates among 191 patients with advanced cancer were high, too 16 …”

What matters to patients and clinicians when discussing the impact of cancer medicines on health-related quality of life? Consensus-based mixed methods approach in prostate cancer

“…As survival rates improve and more patients are living with cancer, a shift away from solely offering supportive palliative care at the end of life [ 5 ] has resulted in an interest in assessing Quality of Life (QoL) among cancer patients throughout their journey [ 6 ], in addition to standard clinical outcomes such as overall survival. Measurement of health-related quality of life (HRQoL), referring to the impact of health, illness, and treatment on QoL [ 7 ], is recognised as important at both the patient and population level.…”

Phase II prospective trial “Give Me Five” short-term high precision radiotherapy for early prostate cancer with simultaneous boost to the dominant intraprostatic lesion: the impact of toxicity on quality of life (AIRC IG-13218)

“…In the current setting, the availability of multiple treatment options, as well as the slow-progressive course of the disease, suggest that PROs may be useful for the decisional process. Although patients' satisfaction is generally high at the end of treatment [24,25], multiple psychological and physical long-term side effects are emerging, ranging from treatment-related symptoms to fatigue and major depressive disorders [26,27]. Furthermore, a consistent underestimation of side effects severity by physician has been recognized [27,28], highlighting the need for a more comprehensive assessment in every-day clinical practice.…”